Guardant Health (GH) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
The meeting was called to order by the Co-CEO and Chairperson, conducted virtually to maximize accessibility for stockholders.
Rules of conduct and agenda were made available on the web portal, with procedures for voting and asking questions clearly outlined.
Only stockholders of record as of April 15, 2024, were eligible to participate and vote.
Board and executive committee updates
The Board of Directors and key executives, including the Co-CEOs and other board members, were present.
Representatives from Deloitte & Touche LLP (auditors) and Gunderson Dettmer (legal counsel) also attended.
Overview of voting outcomes
A quorum was established with proxies for over 97 million shares, representing 79.7% of outstanding shares.
All three Class 3 director nominees were elected by plurality vote.
Ratification of Deloitte & Touche LLP as independent auditors for 2024 was approved by majority vote.
Advisory approval of executive compensation received a majority of votes cast.
Final voting results will be filed with the SEC on Form 8-K within four days.
Latest events from Guardant Health
- Rapid growth in oncology diagnostics and payer coverage drive strong momentum and future expansion.GH
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 44% to $335M; guidance raised as Shield and oncology volumes surged.GH
Q2 2026 - Multi-cancer early detection is poised to transform cancer care, reducing mortality and costs.GH
7th Annual Healthcare Symposium - Strong growth and innovation, with regulatory and commercial catalysts set to drive 2026 performance.GH
TD Cowen 46th Annual Health Care Conference - 2025 revenue up 33% year-over-year, with robust outlook and innovation driving 2026 growth.GH
Q4 2025 - 2028 revenue target raised to ~$2.2B, with accelerated breakeven and major product launches.GH
Investor Day 2025 - Q3 revenue up 34% to $191.5M; Shield launch, ASP gains, and raised guidance highlight growth.GH
Q3 2024 - Q2 revenue up 29% to $177.2M; Shield test FDA approved; 2024 guidance raised to $690–$700M.GH
Q2 2024 - 31% revenue growth, margin gains, and Shield's FDA approval drive strong 2025 outlook.GH
Q4 2024